As i told yal several days ago, they are releasing results on two Third trials Today. The first one has been ongoing since 2021. The physical Human Results are being presented Today.
$Altimmune (ALT.US)$ Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024 Altimmune (Nasdaq: ALT) presented new data from its 12-week Phase 1b trial of pemvidutide in MASLD patients at The Liver Meeting®. The study demonstrated that weekly subcutaneous doses of pemvidutide significantly reduced inflammatory lipids and showed promising effects on cardiovascul...
71179109
:
Phase II is a good time to talk with Big pharma about the potential M&A. Since the phase 2 results are very promising and it will going into phase 3, you know ALT will rock!
$Altimmune (ALT.US)$Exciting times ..! In a market forecasted to be 100 billion by 2030, Altimmune phase 2 results are very promising going into phase 3 trials. Will a partner be announced or are the rumours true a buy out is eminent..!
Altimmune Stock Forum
$Altimmune (ALT.US)$
Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024
Altimmune (Nasdaq: ALT) presented new data from its 12-week Phase 1b trial of pemvidutide in MASLD patients at The Liver Meeting®.
The study demonstrated that weekly subcutaneous doses of pemvidutide significantly reduced inflammatory lipids and showed promising effects on cardiovascul...
Larger Image: tradingview.com...
$Altimmune (ALT.US)$
Will a partner be announced or are the rumours true a buy out is eminent..!
No comment yet